Pfizer Inc. (NYSE:PFE) Shares Sold by Oppenheimer & Close LLC
Pfizer Inc. (NYSE:PFE) Shares Sold by Oppenheimer & Close LLC
Oppenheimer & Close LLC lowered its position in Pfizer Inc. (NYSE:PFE – Get Rating) by 5.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 142,581 shares of the biopharmaceutical company's stock after selling 7,445 shares during the quarter. Pfizer accounts for approximately 8.5% of Oppenheimer & Close LLC's holdings, making the stock its 2nd biggest holding. Oppenheimer & Close LLC's holdings in Pfizer were worth $7,475,000 at the end of the most recent quarter.
Oppenheimer&Close LLC在提交給美國證券交易委員會的最新Form 13F文件中稱，該公司在第二季度將其在輝瑞(紐約證券交易所代碼：PFE-GET評級)的持股比例下調了5.0%。該機構投資者在本季度出售了7,445股後，持有這家生物製藥公司的142,581股股票。輝瑞約佔Oppenheimer&Close LLC所持股份的8.5%，使其成為其第二大持股。截至最近一個季度末，Oppenheimer&Close LLC持有的輝瑞股份價值7,475,000美元。
A number of other hedge funds have also made changes to their positions in PFE. Ullmann Wealth Partners Group LLC increased its position in Pfizer by 6.2% during the 1st quarter. Ullmann Wealth Partners Group LLC now owns 5,759 shares of the biopharmaceutical company's stock worth $298,000 after purchasing an additional 335 shares in the last quarter. Red Door Wealth Management LLC increased its position in Pfizer by 8.6% during the 1st quarter. Red Door Wealth Management LLC now owns 109,620 shares of the biopharmaceutical company's stock worth $5,675,000 after purchasing an additional 8,694 shares in the last quarter. Capital City Trust Co. FL increased its position in Pfizer by 49.9% during the 1st quarter. Capital City Trust Co. FL now owns 8,464 shares of the biopharmaceutical company's stock worth $438,000 after purchasing an additional 2,816 shares in the last quarter. Colonial River Wealth Management LLC increased its position in Pfizer by 52.3% during the 1st quarter. Colonial River Wealth Management LLC now owns 20,988 shares of the biopharmaceutical company's stock worth $1,087,000 after purchasing an additional 7,206 shares in the last quarter. Finally, Annex Advisory Services LLC increased its position in Pfizer by 23.6% during the 1st quarter. Annex Advisory Services LLC now owns 10,279 shares of the biopharmaceutical company's stock worth $532,000 after purchasing an additional 1,966 shares in the last quarter. Hedge funds and other institutional investors own 67.90% of the company's stock.
其他一些對衝基金也調整了他們在PFE的倉位。Ullmann Wealth Partners Group LLC在第一季度將其在輝瑞的頭寸增加了6.2%。Ullmann Wealth Partners Group LLC現在持有這家生物製藥公司5759股股票，價值29.8萬美元，上個季度又購買了335股。紅門財富管理有限責任公司第一季度將其在輝瑞的頭寸增加了8.6%。Red Door Wealth Management LLC現在持有這家生物製藥公司109,620股股票，價值5,675,000美元，上個季度又購買了8,694股。第一季度Capital City Trust Co.FL將其在輝瑞的持倉增加了49.9%。Capital City Trust Co.FL現在持有這家生物製藥公司8,464股股票，價值438,000美元，上個季度又購買了2,816股。殖民地河流財富管理有限責任公司在第一季度將其在輝瑞的頭寸增加了52.3%。殖民地河流財富管理有限責任公司現在擁有20,988股生物製藥公司的股票，價值108.7萬美元，在上個季度又購買了7206股。最後，附件諮詢服務有限責任公司在第一季度將其在輝瑞公司的頭寸增加了23.6%。在上個季度又購買了1,966股後，附件諮詢服務公司現在擁有這家生物製藥公司10,279股股票，價值532,000美元。對衝基金和其他機構投資者持有該公司67.90%的股票。
Pfizer Stock Performance
輝瑞股票表現
Pfizer stock opened at $44.08 on Friday. The stock's 50 day moving average price is $48.24 and its 200 day moving average price is $50.32. The firm has a market capitalization of $247.39 billion, a PE ratio of 8.63, a price-to-earnings-growth ratio of 0.54 and a beta of 0.70. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.20 and a current ratio of 1.42. Pfizer Inc. has a one year low of $40.94 and a one year high of $61.71.
輝瑞股價週五開盤報44.08美元。該股的50日移動均線價格為48.24美元，200日移動均線價格為50.32美元。該公司市值為2473.9億美元，市盈率為8.63倍，市盈率為0.54倍，貝塔係數為0.70倍。該公司的債務權益比率為0.39，速動比率為1.20，流動比率為1.42。輝瑞公司股價一年來最低為40.94美元，一年最高為61.71美元。
Pfizer Dividend Announcement
輝瑞宣佈派息
The business also recently declared a quarterly dividend, which will be paid on Monday, December 5th. Investors of record on Friday, November 4th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 3.63%. The ex-dividend date is Thursday, November 3rd. Pfizer's dividend payout ratio (DPR) is presently 31.31%.
該公司最近還宣佈了季度股息，將於12月5日(星期一)支付。11月4日(星期五)登記在冊的投資者將獲得每股0.40美元的股息。這意味着1.60美元的年化股息和3.63%的收益率。除息日期為11月3日星期四。輝瑞的股息支付率(DPR)目前為31.31%。
Analysts Set New Price Targets
分析師設定新的價格目標
A number of analysts recently commented on the company. SVB Leerink dropped their price objective on Pfizer from $55.00 to $53.00 and set a "market perform" rating for the company in a research report on Friday, July 29th. JPMorgan Chase & Co. set a $57.00 price target on Pfizer in a report on Tuesday, June 28th. The Goldman Sachs Group set a $50.00 price target on Pfizer in a report on Thursday, September 1st. Berenberg Bank set a $44.00 price target on Pfizer in a report on Wednesday, September 14th. Finally, Barclays set a $50.00 price target on Pfizer in a report on Thursday, September 1st. Nine equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $57.00.
一些分析師最近對該公司發表了評論。SVB Leerink在7月29日星期五的一份研究報告中將輝瑞的目標價從55.00美元下調至53.00美元，併為該公司設定了“市場表現”評級。摩根大通在6月28日週二的一份報告中為輝瑞設定了57.00美元的目標價。高盛在9月1日星期四的一份報告中為輝瑞設定了50美元的目標價。貝倫伯格銀行在9月14日星期三的一份報告中為輝瑞設定了44.00美元的目標價。最後，巴克萊在9月1日週四的一份報告中為輝瑞設定了50.00美元的目標價。9名股票研究分析師對該股的評級為持有，10名分析師給出了買入評級，一名分析師給出了強烈的買入評級。根據MarketBeat的數據，該公司目前的共識評級為“適度買入”，共識目標價為57.00美元。
About Pfizer
關於輝瑞公司
(Get Rating)
(獲取評級)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
輝瑞在全球發現、開發、製造、營銷、分銷和銷售生物製藥產品。該公司在不同的治療領域提供藥物和疫苗，包括Premarin系列和Eiquis品牌的心血管代謝和婦女健康；Ibrance、Xtandi、Sutent、Inlyta、Retacritt、Lorbrena和Braftovi品牌的生物製品、小分子、免疫療法和生物仿製藥；舒必樂、Medrol、Zavicefta、Zithromax、Vfend、Panzyga和Paxlovid品牌的無菌注射和抗感染藥物以及口服新冠肺炎治療。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
- 2 Semiconductor Stocks To Watch For Reversals
- 免費獲取StockNews.com關於輝瑞的研究報告
- 華爾街對Datadog的熱情會帶來巨大的收益嗎？
- MarketBeat：回顧一週9/19-9/23
- 為什麼特斯拉的股票保持彈性？
- 好市多盈利後價格疲軟是買入的好時機嗎？
- 需要關注的2只半導體類股走勢逆轉
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).
想看看其他對衝基金持有PFE嗎？訪問HoldingsChannel.com獲取輝瑞的最新13F備案文件和內幕交易。
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
接受輝瑞日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收最新新聞和分析師對輝瑞及相關公司評級的每日簡明摘要。
譯文內容由第三人軟體翻譯。